At the time of writing, Neurogene Inc [NGNE] stock is trading at $22.32, up 9.93%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NGNE shares have gain 12.59% over the last week, with a monthly amount drifted -53.87%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Neurogene Inc [NASDAQ: NGNE] stock has seen the most recent analyst activity on June 27, 2024, when BMO Capital Markets initiated its Outperform rating and assigned the stock a price target of $65. Previously, Robert W. Baird started tracking the stock with Outperform rating on June 11, 2024, and set its price target to $54. On April 29, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $46 on the stock. William Blair started tracking the stock assigning a Outperform rating and suggested a price target of $61 on March 21, 2024. H.C. Wainwright initiated its recommendation with a Buy and recommended $45 as its price target on January 08, 2024. Stifel started tracking with a Buy rating for this stock on January 05, 2024, and assigned it a price target of $31. In a note dated January 04, 2024, TD Cowen initiated an Outperform rating.
For the past year, the stock price of Neurogene Inc fluctuated between $12.49 and $74.49. Currently, Wall Street analysts expect the stock to reach $48.5 within the next 12 months. Neurogene Inc [NASDAQ: NGNE] shares were valued at $22.32 at the most recent close of the market. An investor can expect a potential return of 117.29% based on the average NGNE price forecast.
Analyzing the NGNE fundamentals
Gross Profit Margin for this corporation currently stands at -18.96% with Operating Profit Margin at -105.52%, Pretax Profit Margin comes in at -76.9%, and Net Profit Margin reading is -76.9%. To continue investigating profitability, this company’s Return on Assets is posted at -0.43, Equity is -0.44 and Total Capital is -0.66. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.02 points at the first support level, and at 19.73 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.09, and for the 2nd resistance point, it is at 23.87.
Ratios To Look Out For
It is important to note that Neurogene Inc [NASDAQ:NGNE] has a current ratio of 9.09. As well, the Quick Ratio is 9.09, while the Cash Ratio is 4.22. Considering the valuation of this stock, the price to sales ratio is 464.12, the price to book ratio is 2.11.
Transactions by insiders
Recent insider trading involved Cvijic Christine Mikail, President and CFO, that happened on Nov 22 ’24 when 24000.0 shares were purchased. Chief Executive Officer, McMinn Rachel completed a deal on Nov 22 ’24 to buy 47500.0 shares.
